Angioplasty Balloon Market Scope And Analysis

Report Code : TIPHE100001278
Category : Life Sciences

No. of Pages : 150

Buy Now

Angioplasty Balloons Market Scope and Analysis Report by 2030

Buy Now

Angioplasty Balloons Market Report Scope

Report Attribute	Details
Market size in 2022	US$ 2.71 Billion
Market Size by 2030	US$ 3.60 Billion
Global CAGR (2022 - 2030)	3.6%
Historical Data	2020-2022
Forecast period	2022-2030
Segments Covered	By Type Normal Balloons Drug Eluting Balloons Scoring Balloons Cutting Balloons By Application Peripheral and Coronary By and End User Hospitals Ambulatory Surgery Centers Cath Labs
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Abbott Boston Scientific Corporation Cardinal Health Cook Medical C R Bard Inc ENDOCOR GmbH Medtronic Spectranetics BIOTRONIK

Competitive Landscape and Key Companies:

Abbott, Boston Scientific Corporation, Cardinal Health, Cook Medical, C. R. Bard Inc, ENDOCOR GmbH, Medtronic, Spectranetics, BIOTRONIK, and Terumo Medical Corporation are among the prominent companies profiled in the angioplasty balloons market report. These companies focus on developing new technologies, upgrading existing products, and expanding their geographic presence to meet the growing consumer demand worldwide. As per company press releases, below are a few recent key developments:

In March 2023, in the US, SIS Medical AG introduced the OPN NC PTCA Dilatation Catheter with TWIN-Wall technology. By offering great performance and safety along with success rates where other balloons fail, the product expands therapy possibilities. The OPN NC catheter features a TWIN-Wall design, which offers a super-high pressure resistance with a rated burst pressure of 35 atm with a significantly low compliance.
In September 2022, the FDA granted Advanced NanoTherapies a Breakthrough Device Designation (BDD) for its SirPlux Duo Drug-Coated Balloon (DCB) to treat coronary artery disease. SirPlux Duo DCB delivers low-dose, long-term release of both compounds to inhibit cell growth, resulting in maximum potency exceeding any other DCB or drug-eluting stent.
In January 2022, The Scoreflex NC Scoring PTCA Catheter received Premarket Approval (PMA) from the US Food and Drug Administration (FDA). The Scoreflex NC is a scoring PTCA catheter indicated for the de novo stenotic portion of a coronary artery and in-stent restenosis in coronary arteries in patients evident with coronary ischemia for the purpose of improving myocardial perfusion.